

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 38D2008605	(X3) Date Survey Completed 02/24/2020
Name of Provider or Supplier Advanced Pain Management Center	Street Address, City, State 10305 Sw Park Way Ste 300, Portland, OR	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D5209	<p>PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235</p> <p>As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency.</p> <p>This STANDARD is not met as evidenced by: Based on review of personnel records and interview with the sole testing personnel (TP), the laboratory failed to ensure annual competency assessment was performed on TP in 2019. Findings include: 1. There was no written documentation of competency assessment for the sole TP for 2019. 2. The TP confirmed during interview on 2/24 /2020 at approximately 1200 that competency assessment including the six (6) required procedures according to the federal regulations had not been performed in 2019.</p>
D5217	<p>EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1)</p> <p>At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part.</p> <p>This STANDARD is not met as evidenced by: Based on review of records and interview with the Technical Supervisor (TS), the laboratory failed to ensure bi-annual verification was performed on twelve (12) of fifty four (54) analytes it performs testing for on patient samples. Findings include: 1. Of the fifty four (54) analytes performed by the laboratory, twelve (12) of them lacked bi-annual confirmation. The twelve (12) analytes include: Butalbital, Desipramine, Duloxetine, Imipramine, Levophanol, MDA, MDEA, Naloxone, Naltrexone,</p>

Propoxyphene, Secobarbital, and Tizanidine. 2. This finding was confirmed by the TS during interview 2/24/2020 at approximately 1130.